MiNK Therapeutics (NASDAQ:INKT) Issues Earnings Results

MiNK Therapeutics (NASDAQ:INKT) released its earnings results on Wednesday. The company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.16, Zacks reports.

Here are the key takeaways from MiNK Therapeutics’ conference call:

• MiNK has initiated a randomized Phase II ARDS trial enrolling 90 patients, comparing agenT-797 plus standard care with placebo plus standard care. The company says the protocol could transition seamlessly to Phase III, with preliminary data targeted for the second half of 2026; endpoints include survival and ventilator-free days.
• Management highlighted Phase II gastric cancer results in which median overall survival exceeded 23 months in an immune-primed cohort, with some patients still alive years after treatment. These are company-cited observations from a heavily pretreated population, and follow-up is ongoing.
• MiNK reported that the same agenT-797 product showed different immune activity in cancer and ARDS patient analyses, and said it is evaluating biomarkers that may help identify patients most likely to respond. The findings are early translational evidence, not proof of clinical benefit in the randomized trial.
• MiNK ended the first quarter with approximately $9.5 million in cash, after repaying about $5.2 million of debt and raising roughly $3 million through an at-the-market offering. Management expects at least 12 months of runway, including the ARDS trial, while the cash balance and ATM financing indicate continued funding needs may remain relevant.

MiNK Therapeutics Stock Up 2.8%

MiNK Therapeutics stock traded up $0.28 during midday trading on Wednesday, hitting $10.29. 7,769 shares of the stock were exchanged, compared to its average volume of 100,030. The stock has a market capitalization of $52.48 million, a PE ratio of -4.29 and a beta of 0.49. The company has a fifty day simple moving average of $11.19 and a two-hundred day simple moving average of $11.24. MiNK Therapeutics has a 52 week low of $8.48 and a 52 week high of $16.93.

Analyst Ratings Changes

INKT has been the subject of a number of analyst reports. HC Wainwright assumed coverage on shares of MiNK Therapeutics in a report on Wednesday, November 4th. They set a “buy” rating and a $38.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of MiNK Therapeutics in a research note on Friday, October 2nd. Zacks Research lowered MiNK Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 12th. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $50.00 price objective (up from $43.00) on shares of MiNK Therapeutics in a research note on Wednesday, October 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, MiNK Therapeutics currently has an average rating of “Hold” and a consensus price target of $44.00.

Insider Buying and Selling

In other MiNK Therapeutics news, CEO Jennifer Buell sold 6,938 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $10.56, for a total value of $73,265.28. Following the completion of the sale, the chief executive officer owned 74,195 shares of the company’s stock, valued at approximately $783,499.20. This represents a 8.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 20.40% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for cancer. The company’s platform is based on invariant natural killer T (iNKT) cells, an immune-cell type that can recognize cancer-related targets and help stimulate broader anti-tumor immune responses. MiNK’s lead product candidate, agenT-797, is an allogeneic, or donor-derived, iNKT cell therapy designed to be developed as an off-the-shelf treatment. The candidate is being evaluated for use in oncology, including in combination with other cancer treatments such as immune checkpoint inhibitors.